BRPI0922985A2 - vetor de direcionamento (homing) de receptor de fator de crescimento epidérmico (egfr), método para tratamento de câncer caracterizado por células superexpressando egfr, composição farmacêutica para administração sistêmica. - Google Patents

vetor de direcionamento (homing) de receptor de fator de crescimento epidérmico (egfr), método para tratamento de câncer caracterizado por células superexpressando egfr, composição farmacêutica para administração sistêmica.

Info

Publication number
BRPI0922985A2
BRPI0922985A2 BRPI0922985A BRPI0922985A BRPI0922985A2 BR PI0922985 A2 BRPI0922985 A2 BR PI0922985A2 BR PI0922985 A BRPI0922985 A BR PI0922985A BR PI0922985 A BRPI0922985 A BR PI0922985A BR PI0922985 A2 BRPI0922985 A2 BR PI0922985A2
Authority
BR
Brazil
Prior art keywords
egfr
pharmaceutical composition
growth factor
factor receptor
epidermal growth
Prior art date
Application number
BRPI0922985A
Other languages
English (en)
Inventor
Alexander Levitzki
Alexei Shir
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Publication of BRPI0922985A2 publication Critical patent/BRPI0922985A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Information Transfer Between Computers (AREA)
BRPI0922985A 2008-12-22 2009-12-22 vetor de direcionamento (homing) de receptor de fator de crescimento epidérmico (egfr), método para tratamento de câncer caracterizado por células superexpressando egfr, composição farmacêutica para administração sistêmica. BRPI0922985A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13969808P 2008-12-22 2008-12-22
PCT/IL2009/001210 WO2010073247A2 (en) 2008-12-22 2009-12-22 Egfr-homing double-stranded rna vector for systemic cancer treatment

Publications (1)

Publication Number Publication Date
BRPI0922985A2 true BRPI0922985A2 (pt) 2016-10-04

Family

ID=42104511

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922985A BRPI0922985A2 (pt) 2008-12-22 2009-12-22 vetor de direcionamento (homing) de receptor de fator de crescimento epidérmico (egfr), método para tratamento de câncer caracterizado por células superexpressando egfr, composição farmacêutica para administração sistêmica.

Country Status (20)

Country Link
US (2) US9006406B2 (pt)
EP (3) EP2379597B8 (pt)
JP (1) JP2012513210A (pt)
CN (1) CN102325794A (pt)
AU (1) AU2009332522A1 (pt)
BR (1) BRPI0922985A2 (pt)
CA (1) CA2748125A1 (pt)
CY (1) CY1123371T1 (pt)
DK (2) DK3098239T3 (pt)
ES (2) ES2764396T3 (pt)
HR (1) HRP20192317T1 (pt)
HU (1) HUE047759T2 (pt)
IL (1) IL213739A0 (pt)
LT (1) LT3098239T (pt)
MX (1) MX2011006720A (pt)
PL (1) PL3098239T3 (pt)
PT (1) PT3098239T (pt)
SI (1) SI3098239T1 (pt)
SM (1) SMT202000038T1 (pt)
WO (1) WO2010073247A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102240042B1 (ko) 2012-05-03 2021-04-14 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 상기도 감염 치료용 폴리이노신산-폴리사이티딜산(폴리 (i:c)) 제형
JP6103832B2 (ja) * 2012-06-25 2017-03-29 Hoya株式会社 Ｅｇｆｒ結合性ペプチド
US9431064B2 (en) * 2012-11-02 2016-08-30 Taiwan Semiconductor Manufacturing Company, Ltd. Memory circuit and cache circuit configuration
US10796320B2 (en) * 2013-12-23 2020-10-06 Mastercard International Incorporated Systems and methods for passively determining a ratio of purchasers and prospective purchasers in a merchant location
KR102589295B1 (ko) * 2014-05-14 2023-10-13 타르그이뮨 테라퓨틱스 아게 개선된 폴리에틸렌이민 폴리에틸렌글리콜 벡터
US10698620B2 (en) * 2015-03-27 2020-06-30 Intel Corporation Dynamic cache allocation
EP3319587B1 (en) * 2015-11-17 2019-08-21 Bioncotech Therapeutics, S.L Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
GB201601868D0 (en) * 2016-02-02 2016-03-16 Lytix Biopharma As Methods
CN105669964B (zh) * 2016-03-04 2017-11-21 博瑞生物医药（苏州）股份有限公司 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用
JP7096249B2 (ja) * 2016-09-04 2022-07-05 ターグイミューン セラピューティクス アーゲー ｄｓＲＮＡを標的化するためのキメラタンパク質
US10849921B2 (en) * 2017-05-17 2020-12-01 Bioncotech Therapeutics Sl Pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
IL273195B2 (en) * 2017-09-27 2024-04-01 Targimmune Therapeutics Ag Castration-resistant prostate cancer
CN117338800A (zh) 2018-11-01 2024-01-05 阿尔法陶医疗有限公司 肿瘤内α粒子-发射体辐射和针对细胞内病原体的细胞质传感器的激活
KR20210146952A (ko) * 2019-04-03 2021-12-06 타르그이뮨 테라퓨틱스 아게 암의 치료를 위한 면역요법
WO2020263776A1 (en) * 2019-06-24 2020-12-30 North Carolina State University Nucleic acid compositions including a polyalkyleneimine-alkoxylene polymer and methods of making and using the same
WO2020263770A1 (en) * 2019-06-24 2020-12-30 North Carolina State University Nucleic acid compositions including a polyalkyleneimine-alkoxylene polymer and methods of making and using the same
US10915418B1 (en) 2019-08-29 2021-02-09 Snowflake Inc. Automated query retry in a database environment
IL320618A (en) 2022-11-07 2025-07-01 Targimmune Therapeutics Ag Polyplexes of nucleic acids and targeted pairs containing polyethyleneimine and polyethylene glycol
WO2025238236A1 (en) 2024-05-16 2025-11-20 Targimmune Therapeutics Ag Polyplexes of nucleic acids and targeted conjugates comprising polyethyleneimine and polyethylene glycol

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927792B2 (en) 2002-11-18 2011-04-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Targeted double stranded RNA mediated cell killing
CA2587676A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
US7937291B2 (en) * 2009-04-22 2011-05-03 Visa U.S.A. Inc. Providing an announcement about transactions of a target merchant to a consumer

Also Published As

Publication number Publication date
LT3098239T (lt) 2020-02-10
US20120330998A1 (en) 2012-12-27
EP3098239A1 (en) 2016-11-30
IL213739A0 (en) 2011-07-31
AU2009332522A1 (en) 2011-08-11
DK2379597T3 (en) 2016-12-05
HUE047759T2 (hu) 2020-05-28
PT3098239T (pt) 2020-01-15
EP3098239B1 (en) 2019-10-23
SMT202000038T1 (it) 2020-03-13
CN102325794A (zh) 2012-01-18
EP2379597A2 (en) 2011-10-26
US9006406B2 (en) 2015-04-14
ES2764396T3 (es) 2020-06-03
HRP20192317T1 (hr) 2020-03-20
ES2602753T3 (es) 2017-02-22
EP2379597B1 (en) 2016-08-10
EP2379597B8 (en) 2016-11-30
US20120021006A1 (en) 2012-01-26
JP2012513210A (ja) 2012-06-14
SI3098239T1 (sl) 2020-03-31
CA2748125A1 (en) 2010-07-01
EP3705493A1 (en) 2020-09-09
WO2010073247A3 (en) 2010-08-19
WO2010073247A2 (en) 2010-07-01
CY1123371T1 (el) 2021-10-29
DK3098239T3 (da) 2020-01-20
PL3098239T3 (pl) 2020-04-30
MX2011006720A (es) 2011-10-06

Similar Documents

Publication Publication Date Title
BRPI0922985A2 (pt) vetor de direcionamento (homing) de receptor de fator de crescimento epidérmico (egfr), método para tratamento de câncer caracterizado por células superexpressando egfr, composição farmacêutica para administração sistêmica.
FR2911878B1 (fr) Procede de preparation de polyhydroxy-urethanes.
BRPI0816014A8 (pt) anticorpo humano monoclonal isolado, composição, conjugado anticorpo-molécula parceiro, mólecula isolada de ácido nucléico, vetor de expressão, célula hospedeira, método para preparar um anticorpo anti-mesotelina, método de inibição do crescimento de uma célula tumoral expressando a mesotelina, método de tratamento do câncer em um indivíduo, anticorpo anti-mesotelina isolado, e método de inibir o crescimento de uma célula expressando a mesotelina
SG10201910986QA (en) 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
BRPI0808104A2 (pt) Métodos para preparar e para produzir um polipeptídeo, polipeptídeo, sequência de ácido nucleico isolada, construção de ácido nucleico, vetor de expressão recombinante, e, célula hospedeira recombinante
CL2011002943A1 (es) Anticuerpo triespecifico o tetraespecifico; metodo para la preparacion de dicho anticuerpo; celula huesped; composicion farmaceutica.
BRPI0814781A2 (pt) Proteína, sequência de ácido nucleico, método para a produção de ácido itacônico, vetor, célula hospedeira, e, uso de um ácido cis-aconítico
IL208877A0 (en) Systems, methods and compostions for optical stimlation of target cells
AU2009301431A8 (en) Bispecific anti-VEGF/anti-ANG-2 antibodies
WO2008039974A3 (en) Cancer vaccines and vaccination methods
BRPI0918768A2 (pt) composições de anticorpo recombinante de anti-receptor do fator de crescimento epidérmico.
WO2009107121A8 (en) Medical apparatus and method for attaching a suture to a bone
SI2201012T1 (sl) Derivati pirolo(2,3-D)pirimidina kot inhibitorji proteina kinaze B
SE0700244L (sv) Bakgrundsavsökningsmetod för WLAN-klientenheter
BRPI0813242A2 (pt) Proteína de ligação a antígeno isolada, ácido nucléico isolado, vetor, célula hospedeira isolada, método para a produção de uma proteína de ligação a antígeno, e, composição.
BRPI1011144A2 (pt) proteína precursora, sequência de ácido nucleico, cassete de expressão, vetor recombinante, método para produzir um peptídeo desejado, e, uso de um peptídeo anfifílico.
BRPI0822012A2 (pt) Derivados de quinazolina de 6,7-dialcóxi úteis para o tratamento de distúrbios relacionados com câncer
BR112012010591A2 (pt) "conjugado de moléculas, ácido nucleico e método pe produção de conjugado de móleculas"
WO2013023043A3 (en) Treatment of advanced solid tumors using combination of anti-erbb3 immunotherapy and selected chemotherapy
WO2012138715A3 (en) Small molecule inhibitors of xbp1 splicing
WO2008051539A3 (en) Processes for preparing palonosetron salts
UY31013A1 (es) Metodos para prepar compuestos basados en imidazol
BRPI1009241A2 (pt) anticorpo monoclonal anti-rhd, ácido nucleico, vetor de expressão, célula hospedeira, método para produção de um anticorpo, composição farmacêutica.
BRPI1014942A2 (pt) "polipeptídeo, ácido nucleico, vetor, célula hospedeira, método para produzir um polipeptídeo, composição farmacêutica, e método para tratar uma doença"
WO2010039885A3 (en) Crystalline forms of dexlansoprazole

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]